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The Biological Speciation and Toxicokinetics of
Aluminum
Emily DeVoto1 and Robert A. Yokel2
'Department of Environmental Sciences and Engineering, School of Public Health,
University of North Carolina at Chapel Hill and Division of Pharmacology and
Experimental Therapeutics, College of Pharmacy and Graduate Center for Toxicology,
University of Kentucky, Lexington, KY 40536-0082 USA
Aluminum is one of the most abundant
elements in the environment. Some human
exposure is unavoidable - daily intake is
largely oral and averages 30-50 mg (1). Of
this, no more than about 7 mg is expected
to come from water, based on the maxi-
mum reported concentration of aluminum
in drinking water (2) and the average con-
sumption of 2 1 water/day. Inhalation
exposure is generally negligible, though it
can be significant in some occupational set-
tings, as described below. The contrast
between widespread occurrence and rela-
tively low intake underscores the impor-
tance of speciation in determining the
bioavailability of aluminum, as this metal
is of limited solubility in its environmen-
tally occurring forms. Despite generally
low exposures, the toxicity of aluminum,
particularly to the nervous system, is of
concern. Much research on aluminum in
recent years has focused on its role in the
etiology of Alzheimer's disease (AD), but
epidemiologic studies attempting to link
aluminum with AD in drinking water have
been inconclusive and contradictory. This
review examines sources of aluminum and
the factors determining its absorption, dis-
tribution, and elimination in the body,
with particular reference to the literature
and analytical techniques developed within
the last 10 years.
The chemical forms, or species, of alu-
minum formed in the body have important
implications for the balance between the
metal's uptake into tissues and its excre-
tion. The study of aluminum speciation
has presented a number of major difficul-
ties to researchers. First of all, tracer studies
with the aluminum isotope 26Al are very
expensive due to the rarity and low activity
of the nucleus and also because of the cost
of using accelerator mass spectrometry.
Second, because of aluminum's ubiquity in
the environment, contamination of sam-
ples (from dust particles, for example) is
difficult to avoid. Finally, aluminum metal,
mineral forms, and some salts are very
insoluble except at extremes of pH or in
the presence of chelating ligands.
Aluminum and Alzheimer's Disease
There has been considerable interest and
controversy concerning the relationship
between aluminum in drinking water and
AD. A number of studies (3-8) found cor-
relations between aluminum concentra-
tions in drinking water and the incidence
ofAD, although the relative risk ofAD for
those exposed to the highest aluminum
concentration, compared to those exposed
to the lowest aluminum concentration, was
less than 2 in each case. Michel et al. (9)
found a relative risk of about 4 for those
exposed to the highest aluminum concen-
tration (100 pg/i) compared to the lowest
(10 pg/i). Studies failing to find an associa-
tion were reported by Wood et al. (10) and
Wettstein et al. (11). Although drinking
water aluminum constitutes only a small
percentage of total daily aluminum intake,
Martyn et al. (5) suggested that aluminum
in drinking water "is either dissolved or
readily brought into solution." The alu-
minum in drinking water may therefore
exist as species that are more readily
absorbed than those from other sources of
aluminum. However, there are no reports
on the oral bioavailability of various alu-
minum species in water compared to
species found in food or other sources.
Continuation of the Michel et al. (9) study
failed to show an association between
drinking water aluminum and cognitive
impairment when water pH was not con-
sidered. They observed a positive associa-
tion up to pH 7.3, and a negative associa-
tion at higher pH (12), suggesting a pH-
dependent change in the aluminum species
composition in water. In a review of most
of the studies of drinking water aluminum
and AD, Doll (13) pointed out that low
pH was reported in several of the studies
showing a positive association between alu-
minum concentration and AD; one such
study was that of Frecker (14). In contrast,
the water had a high pH in one of the
studies that failed to show an association
(11).
Odds ratios calculated by Forbes and
McAiney (8), using a logistic regression
model for the association between water
pH and impaired mental functioning, sug-
gest that medium pH, and to a lesser
extent high pH, are protective relative to
low pH. However, the authors did not
state what variables were being controlled
for in the analysis. Forbes et al. (15) and
Forbes and McAiney (8) reported results
suggesting a protective effect of fluoride on
aluminum-associated dementia. This was
not substantiated by the results ofJacqmin
et al. (12). A protective effect of fluoride
might be explained by a fluoride-associated
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decrease in aluminum bioavailability, as
suggested by the results of Ondreicka et al.
(16).
A number of criticisms of the above
studies can be made. First of all, most do
not demonstrate a dose-response relation-
ship. Aluminum exposure measured over
the short-term may not be a good surro-
gate for lifetime exposure, which is espe-
cially important given that AD is a chronic
disease that may have a long latency peri-
od. Consequently, it is also difficult to
establish temporality in the exposure-dis-
ease relationship. Also at issue are the
imprecision in AD diagnosis and the error
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in measurement and extrapolation of data
on exposure to aluminum in drinking
water. Studies with 26Al to determine the
influence of other chemical species and pH
of drinking water on oral aluminum
bioavailability from food and water might
help determine whether enough aluminum
is absorbed from water to impact on alu-
minum body burden. However, such stud-
ies will not directly address the role of alu-
minum in AD. Finally, only a small per-
centage of total oral daily aluminum intake
comes from drinking water.
Specific Sources of Exposure
The aluminum content of foods has been
reviewed by Pennington (1/) and Greger
(18). Common food additives containing
aluminum are acidic sodium aluminum
phosphate, a leavening agent, and basic
sodium aluminum phosphate, an
emulsifier. Aluminum is also found in food
colorings, and anticaking agents may con-
tain aluminosilicates. Processed cheese (a
28-g serving, with 297 pg aluminum/g, has
8 mg) and cornbread (18 mg in a 45-g
serving with 400 pig aluminum/g) are
major contributors to high aluminum
exposures in the American diet. The high
aluminum content of these foods is largely
due to additives. Another significant
dietary source of aluminum is soy-based
milk products, which contribute as much
as 2.1 mg aluminum/day, based on the
typical intake of an infant; this exposure is
of particular concern for infants suffering
from renal deficiency (18).
There has been concern in recent years
about leaching of aluminum from beverage
cans and cookware. Aluminum beverage
cans are generally coated with a polymer
that prevents leaching. The average con-
centration of aluminum in cola drinks was
found to be only 0.1 pg/g. Aluminum
cookware, however, may leach aluminum
into highly basic or acidic foods. Tomato
sauce cooked in aluminum pans was found
to accumulate 3-6 mg aluminum per 100
g serving (18).
Duplicate portion studies in different
populations, in which subjects submitted
for analysis duplicates of the diets they
consumed over a 24-hr period, estimated
the following average daily dietary expo-
sures to aluminum: 3.1 mg [Holland, men
and women (19)], 2.2-8.1 mg Japan, men
(20)], 13.7 mg (USA, men aged 25-30
(17].
The maximum reported concentration
of aluminum in drinking water was 3.5 mg
aluminum/1 (2). Aluminum in U.S.
groundwaters ranged from 0.014 to 0.29
mg/l and in untreated surface waters from
0.016 to 1.17 mg/!. Aluminum sulfate is
often added as a flocculant to surface
waters, resulting in aluminum concentra-
tions in finished drinking water from
0.014 to 2.67 mg/!. Assuming daily con-
sumption of 2 1 of water with an average
concentration of 0.1 mg/I, daily intake of
aluminum from water would be 0.2 mg
(21).
Aluminum in pharmaceuticals has been
reviewed by Yokel (22). Some over-the-
counter pharmaceuticals such as antacids
and buffered aspirin contain sufficient alu-
minum to increase the daily dose
significantly. Many antacids consist of a
mixture of Al(OH)3 and other hydroxides,
such as magnesium. Maalox Extra Strength
tablets, for instance, contain 400 mg
Al(OH)3 and 400 mg Mg(OH)2. The rec-
ommended dose for relief from gastric dis-
comfort is up to eight tablets per day; that
is, 3.2 g Al(OH)3, or 1.1 g aluminum,
which is a 30-fold increase over the average
exposure from food and drinking water
alone. Patients with renal insufficiency
often take large quantities of aluminum-
containing antacids to bind excess phos-
phate. The resulting AlP04 is insoluble,
making the phosphate more easily exc-
retable via the feces. Other potentially
significant exposures, though likely to be
short term, can occur through use of intra-
venous solutions: 10% calcium gluconate
and 3 M potassium phosphate were found
to contain 5.1 mg aluminum/g and 17
mg/g, respectively. Diphtheria-pertussis-
tetanus vaccine, administered widely in the
United States to children and adults, con-
tains an aluminum adjuvant (18).
Dialysis patients can be exposed to
large amounts of aluminum via their dialy-
sis fluid. This exposure has been responsi-
ble for notable episodes of neurotoxicity
(23,24). Toxicity associated with dialysis
fluid can be largely reduced by removing
aluminum from the fluid. Winney et al.
(25) found that treatment of dialysate
water with reverse osmosis led to decreases
in blood aluminum. No new cases of alu-
minum toxicity occurred in Scotland over
5 subsequent years of follow-up among
dialysis patients.
Inhalation exposure of the general pop-
ulation to aluminum in dust is as high as
0.14 mg/day, based on an upper-bound
measurement of 5000 ng/m3 [in urban air
(2)] and typical exposure estimates (1 1
air/breath and 20 breaths/min). In con-
trast, miners, smelters, and other metal
workers can be exposed to toxic levels of
aluminum through dusts and aerosols. A
group of aluminum welders (26), for
example, was exposed to 2.4 mg/m3 of alu-
minum (8-hr time-weighted average),
which results in inhalation of 23 mg over
an 8-hr shift.
Miners in northern Ontario between
1944 and 1979 were deliberately exposed
via inhalation to aluminum dust as a pro-
prophylactic measure against silicosis (27).
Before each shift, miners were exposed to
20,000 to 34,000 ppm aluminum dust in
an enclosed area for 10 min, resulting in
estimated average exposures of 375
mg/year. Exposed and unexposed miners
did not differ significantly in incidence of
neurological disorders, but the exposed
miners achieved lower scores on cognitive
examinations and were more likely to fall
into the "impaired" range.
Techniques for Analysis of
Aluminum and Its Speciation in
Biological Media
Understanding the toxicokinetic behavior
of any chemical requires detailed knowl-
edge of the species it forms in the body,
which determine the extent to which it is
absorbed, how it is transported in the
blood, and its bioavailability to tissues sus-
ceptible to toxicity. The study of alu-
minum has depended largely on equilibri-
um modeling of small-molecule species
expected to form under various physiologi-
cal conditions and on filtration techniques
combined with chromatography to deter-
mine the specificity and extent of alu-
minum's binding to protein. Nonetheless,
it is still not known whether small alu-
minum complexes or protein-bound forms
contribute more to aluminum's toxicity.
For aluminum to be absorbed directly
across cell membranes, it would have to be
in the form of a neutral species.
Alternatively, aluminum could be taken up
in the form of a protein complex by recep-
tor-mediated uptake, such as that occur-
ring with transferrin (see di-scussion
below). Finally, nonspecific uptake of alu-
minum in any form could occur via
pinocytosis.
Atomic absorption. Total aluminum
concentration in biological media is typi-
cally determined using atomic absorption
spectroscopy. This method alone, however,
provides no information about speciation.
Atomic absorption spectroscopy is subject
to contamination because aluminum from
dusts is difficult to avoid. Spectral interfer-
ence from other metals can be minimized
by judicious choice of absorption lines.
The detection limit of flame atomic
absorption spectroscopy for aluminum is
30 ng/ml (1.1 pM). The detection limit
for electrothermal atomic absorption is
considerably lower, [0.005 ng/ml (28)].
High-energy accelerator mass spectrom-
etry. Accelerator mass spectrometry can
measure as few as a million atoms of 26Al
(29). 26Al is a long-lived radioisotope (half-
life of about 105 years) that enables studies
of very low doses of isotopic aluminum.
Day and co-workers (30) and Priest et al.
(31) described the use of 26Al for tracer
studies in humans. A number of investiga-
Volume 102, Number 1 1, November 1994 941
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tors performed similar experiments in rats
(30,32,33); each of these studies is
described below.
Filtration techniques. Gel filtration and
ultrafiltration, combined with atomic
absorption spectroscopy, have been used to
distinguish between protein-bound and
nonprotein-bound aluminum in serum or
serumlike solutions and, to a degree,
among different proteins binding to alu-
minum. "Ultrafiltrable" as used here means
able to pass through an ultrafilter and
refers to small-molecule species such as alu-
minum citrate. Non-ultrafiltrable species
are primarily protein bound but may also
include insoluble or colloidal complexes of,
for example, aluminum hydroxide. It is
important to recognize that, at high con-
centrations, aluminum may precipitate out
as a solid or form a colloid that cannot be
distinguished by ultrafiltration from pro-
tein-bound and otherwise non-ultrafiltra-
ble aluminum.
A number of researchers have attempt-
ed to investigate the nature of aluminum's
binding to serum proteins by gel filtration
techniques (34-39). This approach has
been problematic in a number of respects.
Many columns avidly bind aluminum,
making recovery difficult. Favarato et al.
(37) recovered aluminum from different
columns, by washing with buffer contain-
ing desferrioxamine, in the following
amounts: TSK-GEL HW-5SS, 75%;
Sephadex G-200, 36%; Sephacryl S-500,
30%; and Bio Gel P-2, 24%.
27A1-NMR. Recently, nuclear magnetic
resonance (NMR) directed at the 27Al
nucleus has been used to investigate alu-
minum species in solution. Unlike 13C or
1H, 27A1 has a spin quantum number
greater than 1, resulting in broad signals
when bound to asymmetrically arranged
ligands, which makes structural assign-
ments difficult. Theory and applications of
27A1-NMR have been thoroughly reviewed
by Akitt (40). Results of 27A1-NMR exper-
iments using citrate are summarized in
Table 1. Fatemi et al. (41) demonstrated
aluminum binding to transferrin, albumin,
and citrate. For an aluminum-citrate solu-
tion over the range of pH 6.0-8.4, these
investigators found a double signal in the
region from about 0 to 10 ppm shift. At
the highest pH, Al(OH) was detected, as
well as aluminum-citrate complexes. Feng
et al. (42) detected a trinuclear alu-
minum-citrate species in solution within a
range of intermediate pH. The identity of
this species was confirmed by X-ray crystal-
lography.
Potentiometric data and equilibrium
models. Equilibrium models, based on
potentiometric data, allow a much more
complete (although theoretical) description
of species formed in aqueous solutions of
aluminum with its ligands, compared to
the analytical techniques described in earli-
er sections. In this technique, formation
(or equilibrium) constants are fit to data
on change of pH as a function of acid or
base added to a solution. These constants
can then be used, usually with a computer
program, to predict equilibrium concentra-
tions of the postulated species under
specified concentrations of aluminum and
its ligands, at different pH values. A sum-
mary of the predominant aluminum
species predicted by each model, in the
presence of citrate and range of pH values,
is presented in Table 2.
Berthon and Dayde (43) described a
model of aluminum speciation in the intes-
tine designed to compare the fraction of
neutral aluminum species formed after
administration of either aluminum phos-
phate or aluminum hydroxide. This model
predicted that AI(OH)3 would dissolve
better than AlPO4 in the presence of
organic acids and would complex better
with the acids. Aluminum administered
orally as AI(OH)3 would be better
absorbed in the gut than AlPO4 and thus
lead to the observed increased toxicity.
Furthermore, this dissolution, complexa-
tion, and absorption should be higher in
the proximal jejunum (about pH 7) than
in the duodenum (pH 3-4).
Ohman (44) performed a titration
study of aluminum-citrate speciation over
time in aqueous solution that followed pH
as a function of added base. Speciation was
calculated by curve fitting using published
equilibrium constants. One species,
A1(OH)H_1Cit2 [Al(CitH_1)(OH) -, using
Ohman's convention] was found at physi-
ologic pH in fresh (that is, unaged) solu-
tions. A second species, A13(OH)(H1
Cit)34, predominated in somewhat older
solutions.
On the basis of a similar pH-time
study, Ohman (44) first fitted stability con-
stants for A1(H_lCit)- and AIOH(H_ Cit)2- at
time 0 assuming that the concentration of
A13(OH)(H_1Cit)34- was 0. He then pre-
dicted corresponding concentrations of the
trinuclear species, based on the amount of
hydroxide taken up, as evidenced by the
pH, then constructed distribution dia-
grams over time. In these models, the trin-
uclear aluminum species appeared after 1
min at around pH 6 and then came to pre-
dominate over a broader pH range after a
few minutes.
The existence of this trinuclear species,
A13(OH)(H_1Cit)34-, was confirmed by
Feng et al. (42) and in our laboratory (45)
through the use of 27A1-NMR. We found
further that the trinuclear species indeed
appeared at an aluminum:citrate ratio close
to 1. We were unable to see this species in
solutions where citrate was increased rela-
tive to aluminum, however. Furthermore,
the equilibrium models described below do
not support the existence of this species
under high citrate:aluminum ratios such as
those found in blood. The published
model found to be in best agreement with
the experimental data generated in our lab
was that ofOhman (44). When extrapolat-
ed to physiologic aluminum and citrate
concentrations, this model predicts the
neutral species AlCito only below pH 3.5;
at higher pH the predominant aluminum
species are AlCitH- (pH 3.5-6.5) and
AlOH(H Cit)2- (pH 6.5-8.5) (45).
Motekaitis and Martell (46) examined
potentiometrically the equilibrium
between aluminum and a number of
organic ligands, including citric acid, at
metal:ligand ratios of 1:1 and 1:2.
Equilibration times between additions of
acid or base varied but were not reported.
Only three species were assumed, each of
them a 1:1 aluminum:citrate species in a
different protonation state.
Gregor and Powell (47) assumed that
citrate's hydroxy proton was available to
complex with aluminum, and used a 5.3-
or 6.3-fold excess of ligand over metal for
potentiometric determinations. KI-Cit3-
ion pairing was taken into account because
KOH was used as a titrating base. Eight
aluminum-citrate species were assumed,
but no polynuclear species. 13C-NMR sup-
ported the possibility that the hydroxy pro-
ton was used in bridging.
Martin (48) used adjusted equilibrium
constants from the published literature to
model the binding of aluminum citrate
(assuming no polynuclear species), at ionic
strengths of 0.1 to 0.16 M, and over a pH
Table 1. Nuclear magnetic resonance shifts from published investigations of the aluminum-citrate system
Species Shift (ppm downfield from TMS) Reference
Al(H20)63+ 0 (41)
Aluminum-citrate solution (conditions unspecified) 8,10,12 (40)
Al(OH)- 80 (46,107)
A13(0H)(H_1Cit)34- 0,10,12 (42)
Aluminum-citrate solution 14, 21.1, 28.1 (108)
Equimolar aluminum-citrate pH 2: 0, 8 ppm (109)
pH 3: 10 ppm
Equimolar aluminum-citrate (0.1 M each) pH 2.7: -4 ppm (110)
pH 11.4: -87 ppm
aConditions unspecified; no significant change noted between different mole ratios.
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range of 1-9. At physiologic pH and a
ratio of 100:1 citrate to aluminum, the
species Al(H lCit)- was predicted to pre-
dominate.
Venturini and Berthon (49) examined
the aluminum-citrate equilibrium at phys-
iologic ionic strength and devised a model
containing seven citrate species, including
a trinuclear and a binuclear aluminum
species, and two hydroxy aluminum
species. At physiologic pH and about 60:1
citrate:aluminum, AlCit2(OH)4- [ML2H_1]
by the authors' convention (49)]; Al3(OH
(H 1Cit)34- [M3L3H_4]; and AlCit2(OH)2[ML2H_2] were major species, while the
trinuclear aluminum species (stoichiomet-
rically equivalent to that postulated by
Ohman) predominated at physiological
pH at citrate:aluminum ratios of about 5:3
and 6:1.
Two recent studies suggest that alu-
minum-phosphate species are the predom-
inant small-molecule forms of aluminum
in serum. Dayde et al. (50) titrated an
acidic aluminum chloride/orthophosphoric
acid mixture at different mole ratios over a
wide range of pH to produce formation
constants; the aluminum-phosphate
species best fitting the model were AIP04,
AlHPO4+, AlH2PO42 , A12PO4 ,
Al2PO4(OH)2+, and A12PO4(OH)3'. A
model constructed from these formation
constants and those previously determined
for aluminum citrate and hydroxide pre-
dicted the predominant low-molecular-
weight species, under physiologic condi-
tions, to be Al(OH)3° (51%), AlP040
(41.5%), and Al2PO4(OH)2+ (7.2%).
Harris (51) derived a largely different
set of equilibrium constants for the alu-
minum-phosphate system from linear free-
energy relationships. The two species
judged to be most important in serum
were AlPO40H- and AlP04'. This study
developed a speciation model containing
all ligands found in serum that are expect-
ed to complex appreciably with aluminum,2+ 2+
as well as metal ions (Zn , Ca , and
Mg2+) that compete with aluminum for
binding sites on transferrin. The model
was studied at aluminum and ligand con-
centrations typical of normal or uremic
plasma and at pH 7.4. The following
assumptions were made: 1) the N-terminal
binding site on transferrin is 60% saturat-
ed with iron, which is not displaced by
other metals; 2) aluminum does not bind
to albumin; and 3) trinuclear aluminum
citrate [Al3Cit3(OH)44-] and aqueous
Al(OH)3 exist. Concentrations of organic
ligands in normal serum were taken from
the Geigy Scientific Tables, and formation
constants (other than for phosphate) were
adopted from a number of literature
sources and averaged when more than one
was available. The principal species pre-
dicted from the complete model were alu-
minum-transferrin (about 81%, which
was supported by results obtained with
26Al (31), AlP040H- (about 16%), and a
few hydrolyzed species. Harris's work is the
first published so far to incorporate citrate
and phosphate in the same equilibrium
model and the first to suggest that phos-
phate might be a more significant binder
of aluminum than citrate.
Absorption of Inhaled Aluminum
Although inhalation exposure is not likely
to be of concern to the general population,
miners, smelters, and other metal workers
can be exposed to toxic levels of aluminum
through dusts and aerosols. Elinder et al.
(52) found that two welders, each with
about 20 years of exposure to 3.0-8.9 mg
aluminum/m3, excreted 107-351 pg/l alu-
minum in their urine and had 18-29 pg/g
aluminum in their bones. A group of
workers exposed to aluminum-flake pow-
ders experienced higher whole-blood alu-
minum concentrations (0.33 pM; 8.9 pg/l)
than the comparison group (0.11 pM; 3.0
pg/I) (53). Welders exposed to aluminum
fumes excreted aluminum in urine at a
median concentration of 82 pg/l (3.0 pM)
(54). Foundr workers exposed to <1 mg
aluminum/m (55) for a median of 7 years
experienced increased serum aluminum
concentrations compared to controls, but
urinary excretion was unchanged.
Exposure of rabbits to 0.56 mg alu-
minum/m3 over 5 months led to an 15.8-
fold increased accumulation of aluminum
in lung (compared to controls), a 2.5-fold
increase in brain, and a 1.65-fold increase
in kidney (56). It has been estimated that
about 3% of aluminum is absorbed into
the blood from the lung (2).
Absorption ofAluminum in the
Gastrointestinal Tract
The commonly cited estimate of gastroin-
testinal aluminum absorption of 0.1-0.3%
(1,21) was based in part on the assumption
that urinary excretion represents absorp-
tion, which does not take into account tis-
sue distribution, as discussed below. Other
studies (2,30), one using 26Al in a human,
suggest that 1% is absorbed from the gas-
trointestinal tract. However, Schonholtzer
et al. (57) found <0.1% of an oral dose of
26AI (as hydroxide) in the urine of normal
rats and rats with five-sixths of each kidney
surgically removed ("5/6 nephrectomy") in
the first 300 min after dosing. Considering
the rapid urinary elimination of most alu-
minum (31), these results suggest <0.1%
oral absorption of the 26Al. Jouhanneau et
al. 633) found only 0.02% of an oral dose
of Al, as the citrate, in urine and another
0.02% of the dose in the liver of rats, sug-
gesting absorption of only 0.04% from the
gastrointestinal tract.
Some absorption of aluminum may
occur in the stomach (58); the majority of
aluminum absorption, however, is expect-
ed to occur in the intestine. In general, the
two-step absorption process in the gut is 1)
lumen--mucosa and 2) mucosa-+bloodstream.
Aluminum must be in the form of neutral
complexes in order to be absorbed by dif-
fusion through the plasma membrane of
cells. Ionic aluminum may be absorbed
actively by specialized iron-absorption
pathways in the gut, as discussed below.
The most important aspect of the gas-
trointestinal tract with regard to its uptake
of aluminum is its change in pH, from 2
to 3 in the stomach to 3 to 8 in the small
intestine. The low pH of the stomach
allows for complete dissolution of, for
example, Al(OH)3 in antacids. This disso-
lution yields free aluminum (Al3+) that is
thus made available for complexation and
possible absorption. Studies of intestinal
uptake that fail to specify or control for
pH must therefore be considered unreli-
able.
The contents of the gut obviously vary
gready between individuals and species and
have an important impact on absorption of
aluminum. The presence of citric acid and
other carboxylic acids have the potential to
form neutral species but may also serve
simply to redistribute aluminum from
insoluble to soluble forms, making the
metal more available for active-transport
pathways. Silicic acid, a form of silicon, on
the other hand, ties aluminum up as insol-
uble complexes that make it less bioavail-
able, as discussed below.
Animal Studies. Addition of citric acid
(0.1 1 1 M) to drinking water containing 0,
100, or 500 mg aluminum/l as the chlo-
ride significantly increased tibial, plasma,
urinary, and fecal aluminum over 12
weeks, suggesting that citrate increases alu-
minum absorption (59). The same study
found that addition of 0.111 M ascorbic
acid to the water increased urinary and
fecal aluminum. Absorption of aluminum
chloride by the in situ rat gut preparation
was significantly increased by addition of
equimolar citrate (2.5 x 10-3 M) to the
perfusate (60).
Domingo et al. (61) compared the
effect of organic acids (ascorbic, gluconic,
lactic, malic, oxalic, and tartaric) on tissue
and urinary concentrations of aluminum
compared to the effect of citric acid in rats
administered aluminum by gastric intuba-
tion. Each of these acids has fewer dissocia-
ble protons than citric acid, which can lose
three protons in order to bind to A13+; for
the most part, administration of these acids
resulted in higher tissue concentrations
than did citrate. Ascorbic acid's effect on
tissue accumulation of aluminum after 5
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weeks of exposure was similar to that of
citric acid, except for kidney, which had a
significantly higher accumulation of alu-
minum after ascorbic acid administration.
Organic acid-induced urinary excretion of
aluminum would have provided further
evidence of increased gastrointestinal
absorption, but no significant changes in
urinary aluminum were found as a result of
administration of the organic acids studied.
Human studies. The effect of gastric
pH on absorption of aluminum was exam-
ined by Rodger et al. (58). These investiga-
tors administered either placebos or raniti-
dine, a drug that suppresses production of
stomach acids (and would thus elevate gas-
tric pH), to healthy subjects and to
patients with renal disease, followed by
AI(OH)3. The subjects who received place-
bos had higher levels of urinary excretion
of aluminum than those who received rani-
tidine, implying that low gastrointestinal
pH promotes absorption of aluminum.
It has been suggested that patients with
AD might have a genetic tendency to
absorb excessive amounts of aluminum. To
test this hypothesis, Taylor et al. (62)
administered an aluminum citrate-contain-
ing drink to 20 AD patients and 20 age-
and sex-matched controls, measuring
blood aluminum before and after con-
sumption of the drink. The investigators
found a greater increase in blood alu-
minum among younger AD subjects than
controls, but not among the older AD sub-
jects compared to their controls. This
study could have been improved by using a
study population large enough to allow
sufficient statistical power for stratified
analysis or randomization. Furthermore, as
has been reported elsewhere, there was
considerable variability among measured
serum aluminum concentrations, which
could have been due to a contamination
problem or the result of confounding by
unstratified exposure variables.
The measurement of total aluminum
concentration in urine before and after
exposure is the simplest, although probably
not the most accurate, means of assessing
absorption. Coburn et al. (63) adminis-
tered 950 mg calcium citrate four times
daily and/or 2.4 g AI(OH)3 daily to eight
normal men. Baseline aluminum excretion
was 0.24 jig/mmol creatinine. Excretion
increased somewhat upon ingestion of
AI(OH)3, but was much higher (by a fac-
tor of 5.3 to 11.1) when calcium citrate
and Al(OH)3 were ingested together, com-
pared to A1(OH)3 alone. Presumably, solu-
ble citrate becomes available to complex
with aluminum, making it more absorb-
able, which is consistent with other studies.
Walker et al. (64) similarly found that
sodium bicarbonate had a lower ability
than sodium citrate to increase aluminum
excretion, and Nolan et al. (65) found that
calcium acetate increased urinary alu-
minum excretion much less than did calci-
um citrate. Maximum urinary excretion of
aluminum, after coadministration with cal-
cium citrate, was 176 ± 103 compared to 6
± 3 pg/g creatinine/day when only
AI(OH)3 was taken (65).
House (66) examined risk factors for
elevated serum aluminum in a group of 71
office workers. Higher serum aluminum
was associated with antacid consumption
and with the batch in which the sample was
analyzed, which strongly suggests sample
contamination problems. Consumption of
cola drinks from aluminum cans appeared
to be inversely related to serum aluminum,
but this was believed, again, to be an arti-
factual result of the high variability due to
contamination. Therefore, no conclusions
can be drawn from this work with regard
to absorption of aluminum from soda
cans.
Edwardson et al. (67) measured uptake
of 6A dissolved in orange juice containing
no added silicon or 100 pM silicon and
found that silicon reduced the amount of
26Al measured in serum. It has been
hypothesized that dissolved silicates in
drinking water may protect against alu-
minum-associated AD by complexing with
aluminum and making it less bioavailable.
Mechanisms ofAluminum Absorption
from the Gastrointestinal Tract
Absorption of aluminum from the gas-
trointestinal tract, if purely passive, would
require that the metal be in some neutral
form in order to diffuse across membranes.
Equilibrium models suggest that this sce-
nario requires very specific conditions of
pH and concentrations of the appropriate
complexing ions. If, on the other hand,
active transport mechanisms predominate,
it is possible that transport could occur
under a broader range of chemical condi-
tions, such as the wide variety of pH and
chemical compositions found in the gas-
trointestinal tract.
Role of active transport and iron ab-
sorption pathways. Feinroth et al. (68)
examined absorption of aluminum using a
rat everted gut-sac, maintained at pH
7.35-7.42. Absorption was inhibited by
dinitrophenol and by the absence of glu-
cose, both of which inhibit cellular respira-
tion, suggesting that aluminum is actively
transported out of the intestine. As alu-
minum behaves similarly to iron in many
biological systems (for example, binding to
transferrin, discussed below), A13+ may also
be taken up via the specialized iron absorp-
tion pathways found in the gut. As evi-
dence for this hypothesis, iron deficiency
has been found to increase the absorption
of aluminum in rats (69) and in renally
impaired humans (70 ). Others, in con-
trast, found that administering extra iron
orally to dialysis patients did not prevent
absorption of aluminum from phosphate
binders (71), which would have implied
competition between aluminum and iron
for absorption. Investigators using an
excised gut-section model found that Fe2+
enhanced disappearance of aluminum from
the intestinal lumen but did not increase
systemic or portal blood aluminum. Fe3+
had no effect on uptake of aluminum from
the intestinal lumen (72).
An iron-binding protein has recently
been identified in the duodenal mucosa of
rats and humans that may prove to bind to
aluminum as well and may thereby
account for part of the mechanism of alu-
minum's uptake at the gut. The protein,
named mobilferrin after the Alabama city
in which it was discovered, is biochemical-
ly and immunologically distinct from both
ferritin and transferrin, the two major
iron-binding proteins in blood, as assessed
by molecular size (56,000 daltons), elec-
trophoretic mobility, and amino acid com-
position. The dissociation constant for iron
from mobilferrin was found to be 8.92 x
105 (73). The physiologic role of this pro-
tein is not yet known; to date it has only
been isolated from duodenal homogenates.
Role ofcitrate. Citrate has been shown
in a number of experimental investigations
to increase markedly the gastrointestinal
absorption of aluminum. It is also a com-
mon component of human diets. The
polyanion of triprotic citric acid, citrate
forms stable complexes with A13+, possibly
resulting in, among other species, a neutral
molecule (AlCio) at low pH that can be
absorbed into the blood or make alu-
minum available to iron-transport path-
ways. It is possible that the hydroxy proton
of citrate may also be involved in the cit-
rate-aluminum coordinate bond at physio-
logic pH, in a proposed trinuclear alu-
minum complex. Based on stability con-
stants, Martin (48) predicted that the max-
imum concentration of the neutral alu-
minum-citrate complex, at 1 piM alu-
minum (about five times greater than nor-
mal), would occur at pH 3 (close to that of
the upper intestine, where much absorp-
tion activity takes place) and 10 mM cit-
rate. Other models predict considerably
lower concentrations of this species, as dis-
cussed in the earlier section on equilibrium
modeling.
Citrate-enhanced absorption of alu-
minum is, however, at least in part an
energy-dependent process. Van der Voet et
al. (74) based this conclusion on their
observation that administration of dinitro-
phenol, which inhibits respiration by
uncoupling oxidative phosphorylation,
decreased the citrate-mediated disappear-
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ance of aluminum from the intestinal
lumen. As mentioned above, citrate
increased absorption of aluminum as the
chloride from the in situ rat gut prepara-
tion (60).
Froment et al. (75), in an examination
of the mechanism of enhancement of alu-
minum uptake by citrate, tested the
hypothesis that citrate increases the perme-
ability of the tight junctions between
intestinal epithelial cells. The investigators
excised the duodena of rats, added a solu-
tion of ruthenium red, and filled each gut
section with either aluminum chloride or
aluminum citrate. Examination of the iso-
lated duodenal sections by transmission
electron microscopy, in the presence of alu-
minum citrate, revealed infiltration of
ruthenium red through the tight junctions,
supporting the hypothesis. In addition, alu-
minum citrate was found to decrease the
transcellular electrical resistance of tight
junctions. The investigators did not exam-
ine the effect of citrate alone, however.
Schonholtzer et al. (32) found that
when 26Al was administered to rats as alu-
minum citrate or aluminum maltolate, 0
to 300-min urinary 26Al was 0.7 and 0.1%
of the dose, respectively. After administra-
tion of the 26Al citrate with 1 mmol/kg
sodium citrate, 5.3% of the 26Al was found
in the urine in the first 300 minutes, sug-
gesting that citrate increased intestinal per-
meability to aluminum citrate.
Aluminum in Blood
Because of the high concentration of
potential ligands relative to the concentra-
tion of the metal, aluminum is expected to
be entirely soluble in blood at concentra-
tions up to at least 100 pg/l. Based on
more than 50 literature sources, Ganrot (1)
reported that the most credible values for
serum aluminum are in the range of 1-5
pg/l, or 0.037-0.185 pM; he judged that
values much higher than these stem largely
from contamination. More recently, Wang
et al. (76) measured levels of aluminum in
63 Canadians by Zeeman atomic absorp-
tion spectroscopy and found an average of
0.06 + 0.05 jiM (1.62 jig/l) in serum and
0.20 ± 0.10 jiM (5.4 pg/l) in urine.
Fulton and Jeffery (59) examined the
effect of dietary citrate or ascorbate on the
absorption of aluminum from drinking
water and subsequent tissue concentrations
and excretion. They found a dose-depen-
dent increase in aluminum concentration
in bone, stomach, intestine, and kidney;
liver aluminum was 1.5-fold greater than
controls, but there was no dose response,
and no aluminum was observed in brain.
Ascorbate and citrate increased the concen-
tration of aluminum in tibia, plasma,
urine, and feces. Plasma aluminum (about
0.7 jM) was less than 0.5% of total blood
Table 2. Equilibrium model predictions for the equimolar aluminum-citrate system: species predicted to
predominate over a range of pHa
Reference Species pH range of predominance
(44) Al3+ <2.5
AlCito 2.5-2.8
A13(OH)(H_1Cit)34- 2.8-8.3
A13(OH)4(H_1Cit)37- 8.3-9.7
AlCitH+ Minor, 2-2.75
AI(CitH_)(OH)2- Minor, >6
AI(H1Cit)- Minor, 2.5-5
(46) Al3+ <2.9
AlCitH+ 2.9-3.1
AlCito 3.1-3.4
AlCit(H_1) (AIH_,Cit) 3.4-8.3
AI(OH)4 <8.3
(48) Al3+ <2
AlCito 2-2.6
AlCit(H_1Y- 2.6-6.5
AlCit23- 6.5-7.5
AI(OH)4- >7.5
(47) Al3+ <1.6
AlCitH+ [AIHL+] 1.6-2.6
AlCito [AIL] 2.6-6.3
Al(OH)4- >6.7
AlCit2OH [AlL2H 14-1 Minor, 5-7.2
(49)b Al3+ [M3] <1.75
AlCitH+ [MLH] 1.75-2.3
AlCito [ML°] 2.3-2.6
Al2Cit2(OH)22 [M2L2H12] Minor, 6.0
A13(OH)(H_,Cit)34- [M3L3H14] Minor, 6.0-10
AI(OH)4- >10
AlCit2(0H)23-
[ML2H_2] Minor, 10-11+
aFormulas in brackets represent authors' original designations.bCalculations based on published equilibrium constants.
Table 3. Concentrations of components in serum available to bind aluminum (51)
Component Binding capacity Component Binding capacity
Albumin 630 pM Histidine 77.0 pM
Cystine 10.9 pM Lactate 1.51 mM
Citrate 99.0 pM Oxalate 9.20 pM
Cysteine 33.0 pM Phosphate 1.10 mM
Glycine 2.30 mM Sulfate 330 pM
Glutamate 60.0 pM Transferrin 49 pMa
aActual aluminum binding capacity, because there are two sites per molecule, and 30% of sites are nor-
mally occupied by iron.
aluminum, which is inconsistent with
other studies and particularly surprising
given that transferrin is a plasma protein.
Red blood cell aluminum did not vary
with dose of aluminum, whereas plasma
aluminum did, which is consistent with
other work. Plasma aluminum concentra-
tions were within the range of values
reported by other studies (1).
Nature and amounts of carrier mole-
cules. Although many of the ligands found
in the gut are also found in the blood
(Table 3), the major plasma binder of alu-
minum is transferrin, an iron-transport
protein that also binds other metals,
including aluminum, at two specific bind-
ing sites. Some nonspecific aluminum
binding may also take place with albumin,
and at least two other aluminum-binding
proteins, an 8 kDa component (38,77) and
an 18 kDa component, albindin (38).
Transferrin, which appears to be the
major ligand for aluminum in serum, is a
protein of 76-80 kDa (78). It is similar in
size and amino-acid sequence to albumin,
but binds metals (particularly iron) with
high specificity at two independent binding
sites with similar metal-binding affinities.
Binding of a metal ion to transferrin
involves deprotonation of three tyrosine
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residues and concomitant binding of a
bicarbonate ion (whose concentration is
not limiting in serum). Transferrin is nor-
mally 30% saturated with iron (79).
Although its usual concentration in serum
is 37 pM (51), lower levels have been found
in dialysis patients, about 30 pM (79).
Bertsch and Anderson (80) studied the
speciation of the aluminum-citrate system
using ion chromatography. They found
that only two peaks were eluted, one con-
taining hexaaquo (fully hydrated) alu-
minum and the other apparently contain-
ing neutral aluminum citrate and
AlHCitr. Other singly charged species
were not distinguishable from the second
peak and, presumably, more highly
charged species were undetectable. Citrate
complexes were highly sensitive to changes
in ionic strength.
Binding to serum proteins. Perez
Parajon et al. (81) evaluated two ultrafiltration
methodologies: conventional ultrafiltra-
tion, using Amicon Diaflo YM10 and
DDS GR61PP membranes, and ultrami-
crofiltration, using the Amicon MPS-1 sys-
tem with a 30 kDa YMT membrane, for in
vitro fractionation of aluminum.
Contamination was a large problem in
both systems. These investigators found,
using the Amicon MPS-1 system, that
8.3% of serum aluminum from normal
subjects and 13.3% of that from patients
with lower than normal renal function
(i.e., uremic) was ultrafiltrable.
Yokel and McNamara (82), using the
MPS-1 system, found that a greater pro-
portion of aluminum was ultrafiltrable in
the serum of renally impaired rabbits than
in serum from renally competent animals.
These results were obtained after incuba-
tion of aluminum with rabbit serum in
vitro and after an intravenous dose of 100
pmol/kg. These investigators also com-
pared the ultrafiltrability of different alu-
minum salts in bicarbonate buffer and
found that the citrate salt of aluminum
remained completely ultrafiltrable up to a
total aluminum concentration of 1 mg/ml,
while aluminum chloride, nitrate, and lac-
tate salts decreased in ultrafiltrability when
total aluminum exceeded 0.01 mg/ml. The
concentrations at which aluminum was not
totally ultrafiltrable were above the high
end of the expected range of serum con-
centrations. Two of the rabbits in this
study died prematurely, possibly (accord-
ing to the authors) from kidney stones,
which could conceivably have consisted of
precipitated aluminum.
The similar sizes of transferrin and
albumin make it difficult to separate these
proteins chromatographically, and failure
to add bicarbonate to the elution buffer
can decrease or prevent binding of alu-
minum to transferrin. Many authors have
assumed that aluminum binds to both pro-
teins, although evidence discussed below
suggests that binding to albumin is
insignificant. Martin et al. (83), based on
the weak binding of aluminum to albumin
in vitro, the high competition in vivo for
albumin binding sites, and the generally
low affinity of metal ions for albumin,
argued against significant in vivo binding
of aluminum to albumin. This would be
particularly true under uremic conditions,
where potential binding sites on albumin
are likely to be occupied by other ligands
that accumulate in serum.
Day et al. (30) administered an oral
dose of 100 ng 26A1 and about 1 pg 27
(natural aluminum) in sodium citrate solu-
tion to a human volunteer. The highest
plasma 26Al concentration measured was
0.3 ng/l at 6 hr after ingestion, which sug-
gests that at least 1% of the administered
dose (assuming a plasma volume of 3 1)
was absorbed (that is, this concentration
does not account for aluminum that has
already been distributed to tissues or elimi-
nated). The study confirmed, by gel per-
meation chromatography and anion
exchange chromatography at pH 7.4, that
80% of aluminum in plasma was associat-
ed with transferrin, 15% existed as other
high molecular weight (>5 kDa) complexes
(including albumin), and 5% as low mole-
cular weight species. Ion-exchange chro-
matography, however, may cause redistrib-
ution of ionic aluminum among proteins,
so the findings of protein-specific binding
are not reliable.
Favarato et al. (38) compared the pro-
tein binding of aluminum in serum among
renally competent workers exposed and
unexposed to aluminum and detected a
novel protein, dubbed "albindin." This
protein picked up more than 40% of
serum aluminum after treatment of the
serum with desferrioxamine, a powerful
chelator of trivalent metallic cations. The
amino-acid composition of albindin was
distinct from that of transferrin or albumin
(38). The protein-binding profile of alu-
minum was most complex in the more
highly exposed group of workers (classified
on the basis of total serum aluminum con-
tent). Proteins were identified by polyacry-
lamide gel electrophoresis (SDS-PAGE),
but transferrin and albumin could not be
resolved chromatographically (38).
Cochran et al. (39) eluted plasma
(which had been spiked with aluminum)
from uremic patients on Sephacryl S-300
and assessed the reproducibility of the alu-
minum/transferrin and aluminum/albu-
min molar ratios in adjacent elution frac-
tions. They found that the aluminum:
transferrin ratio remained at about 0.12,
whereas aluminum/albumin varied from
0.002 to 0.024. These results provided evi-
dence for an association between alu-
minum and transferrin but not albumin.
Transferrin and albumin concentrations
were assessed by immunodiffusion, but the
methods used were neither described nor
referenced. The overall recovery of alu-
minum was not reported for this experi-
ment, so the significance of the results is
uncertain. Dialysis of purified albumin
against aluminum solution resulted in the
association of 10% of the aluminum with
albumin, but when calcium and phosphate
were added, no association of aluminum
with albumin was detectable. There was no
evidence of association of aluminum with
either the Sephacryl S-300 or Sephadex G-
50 gel used by Cochran et al. (39).
Role of transferrin. Evidence for trans-
ferrin's role as an aluminum carrier is
strengthened by a study by Cannata et al.
(69) that showed increased aluminum lev-
els in the urine and brain of rats depleted
of iron and exposed orally to aluminum).
This phenomenon may occur because
reduced iron stores lead to increased pro-
duction of transferrin (84,85), a central
concept in iron homeostasis. Cannata et al.
also found that iron-depleted rat intestinal
epithelial cells in vitro contained signifi-
cantly more aluminum when exposed to
transferrin-bound aluminum than did nor-
mal cells (69). Although these results,
which show aluminum retention, may
reflect aluminum uptake into tissues in
general, this evidence is not specifically rel-
evant to the intestine because transferrin is
not found in the intestinal lumen.
In vitro analytical chemical methods
such as titration have been used to estimate
the affinity of aluminum (and other met-
als) for transferrin and other potential
chelators found in serum. Transferrin's
affinity for iron is considerably higher than
for aluminum [e.g., log Kj = 22.7 and log
K2= 22.1 for Fe3+ (83) compared to log K.
= 13.72 and log K2 = 12.72 for A13+ (51).
Because aluminum is present in small
amounts in the blood relative to iron con-
centrations and the capacity of transferrin
to bind aluminum (as discussed above),
and because iron normally occupies only
30% of available sites on transferrin, alu-
minum binding to transferrin is not
expected to be limited by either the con-
centration in blood of transferrin (37 PM)
(51) or of iron.
Kinetics ofAluminum Uptake by
Cells
As in the gastrointestinal tract, aluminum
may be taken up into cells by mechanisms
similar to those used to take up iron.
Foremost among such mechanisms is
receptor-mediated uptake of transferrin-
bound metal, which is saturable. Small-
molecular forms of aluminum may be
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taken up via diffusion of ions or via
pinocytotic uptake of small amounts of
extracellular fluid.
Several investigators have examined the
uptake kinetics of transferrin and iron by
cells. Cole and Glass (86) found binding of
iron to transferrin was not saturated at iron
concentrations up to 50 pM. Iron uptake
by mouse hepatocytes increased with
increasing transferrin concentrations, but
nonspecific uptake (pinocytosis and/or dif-
fusion) accounted for 10-20% of uptake.
Dissociation constants of 0.081 pM (for
suspended cells) and 0.29 pM (for plated
cells) were reported for the dissociation of
transferrin from cells. Page et al. (87)
found similar results using cultured rat
hepatocytes. Cochran et al. (88) examined
the competition between aluminum and
iron for transferrin binding and uptake in
reticulocytes (immature red blood cells).
Binding was significantly less strong in
these cells (Kd = 3 pM) than Cole and
Glass (86) reported for hepatocytes.
Furthermore, aluminum + radiolabeled
transferrin (5 pM) was taken up 1.8 times
faster than labeled iron-transferrin. Iron
uptake reached a plateau by 40 min; alu-
minum uptake, in contrast, continued to
increase after 40 min. In addition, uptake
of radiolabeled iron-transferrin was inhib-
ited to a greater extent by addition of unla-
beled iron-transferrin than by addition of
aluminum-transferrin. The authors postu-
lated a post-uptake feedback mechanism to
regulate uptake of iron, which does not
appear to have an effect on uptake of alu-
minum (88). McGregor et al. (89) report-
ed that aluminum in the form of an AlC13
solution became associated with cells
(probably nonspecifically) more than did
aluminum in a citrate solution. This may
occur because, at physiologic pH, alu-
minum from AICl3 would be expected to
be hydrolyzed to colloidal Al(OH)3°, in
contrast to aluminum citrate, which forms
only charged species at intermediate pH.
Interestingly, in contrast to the results
of Cochran et al. (88), transferrin-bound
aluminum downregulated the number of
cell-surface transferrin receptors on human
erythroleukemia K562 cells to a greater
degree than iron did (90). It is possible
that hepatocytes possess a regulatory mech-
anism for transferrin receptors that is dif-
ferent from that in cultured leukemia cells.
Alternatively, there may be an interspecies
difference, as Cochran et al. used rat hepa-
tocytes, but the differences may also be due
largely to the different study designs.
Pharmacologic Behavior ofAlumin-
um: Distribution and Excretion
After gastrointestinal absorption (or intra-
peritoneal injection), aluminum travels via
the portal circulation into the liver, where
it is thought to undergo a first-pass clear-
ance; that is, much is removed from the
bloodstream (91).
A 41-year-old male volunteer given
26Al intravenously as aluminum citrate
excreted all but 10-15% of the aluminum
during the first day (31). However, 7% of
the aluminum remained 170 days after the
injection, at which time the authors esti-
mated the clearance half-time to be >1
year. Analysis of their results by RSTRIP
(92), a program for pharmacokinetic
analysis, showed that the terminal elimina-
tion half-lives of 26Al that could be esti-
mated in blood and the whole body were
about 7 and 300 days, respectively.
However, the confidence in this estimate
of a 300-day half-life, based on samples
collected to only 170 days, is not great.
Further analysis of these results suggests
that the whole-body aluminum elimina-
tion half-life increases with time after
exposure. This phenomenon might be
explained by the retention of aluminum in
a chemical species different from that
administered. This species may represent a
depot of aluminum that might serve as an
aluminum source within the body as it is
slowly eliminated from its site of distribu-
tion. The whole-body retention of 7% of
the administered aluminum 6 months after
dosing suggests the prolonged residence of
a significant fraction of the administered
aluminum. With continued exposure the
aluminum depot would be expected to
increase. The result would be an increase
in aluminum over the human life span, as
reported for brain aluminum (93).
Much of the work conducted thus far
on aluminum speciation and distribution
has looked at exposures other than inges-
tion, such as intravenous injection, which
can bypass the first-pass effect of the liver.
Exposure to dialysis fluid can be consid-
ered analogous to intravenous injection
because the bloodstream is directly
exposed, without being filtered first by the
liver.
Implications of speciation for alu-
minum excretion and aluminum in ure-
mia. The ionic milieu and speciation of
aluminum in various body fluids are
important to the nature and rate of alu-
minum elimination by various routes.
Aluminum is excreted primarily in the
urine, as described above, and to a small
degree in the feces (largely as insoluble alu-
minum phosphate) by way of the portal
circulation, liver, and bile. Xu et al. (94)
found that biliary excretion accounted for
<1% of the aluminum administered as the
sulfate to rats, whereas urinary elimination
accounted for 9-17%. Greater than 80%
of an intravenous dose of Al citrate was
eliminated in the urine of a human within
2 weeks, whereas <2% appeared in the
feces (31). The relative contributions of
each route of excretion depend in part on
such factors as the solubility of aluminum
species, presence of complexing ions in
serum, renal competence, and aluminum
dose. Under normal renal conditions, alu-
minum should be excreted in urine in the
form of small, charged, and thus water-sol-
uble ions or complexes with anions such as
citrate and phosphate. Renal. dysfunction
could result in the excretion of protein-
bound aluminum as well.
Uremic animals and humans seem to
be more susceptible to aluminum accumu-
lation and toxicity than renally competent
subjects, even in the absence of dialysis.
Alfrey et al. (95) found that nondialyzed
uremic patients experienced aluminum
burdens in liver 6.3 times, spleen 12 times,
bone 6.2 times, and brain 1.7 times higher
than renally competent patients. Dialyzed
uremics and, in particular, dialyzed ure-
mics suffering from encephalopathy, had
tissue burdens many times higher than
nondialyzed uremics.
Hosokawa and Yoshida (96) performed
5/6 nephrectomy on rats and collected
serum 3 months later, without administer-
ing additional aluminum above the normal
dietary exposure. They found that the
average concentration of aluminum in
serum was more than 10 times that seen in
renally intact rats, and the concentration in
kidneys was about 10 times higher. Arieff
et al. (97) obtained results similar to
Alfrey's human data for concentrations of
aluminum in liver of nonuremic dogs and
uremic rats but, in contrast, they found
that brain aluminum was higher in nondia-
lyzed than dialyzed chronic renal failure
patients. No information was given on the
aluminum content of the water used in
dialysis. It is possible that, if water contain-
ing little or no aluminum was used to pre-
pare the dialysis fluid, dialysis could have
cleared the blood of small-molecule alu-
minum, although most aluminum is not in
this form. Another explanation could be
dietary or therapeutic differences between
dialyzed and nondialyzed individuals that
would result in the administration or gas-
trointestinal absorption of different total
quantities of aluminum.
There are a number of possible reasons
for the observation that uremia leads to an
increased body burden of aluminum. The
simplest explanation is that, in having
lower excretory capacity, uremics might
simply not be able to rid themselves of alu-
minum efficiently, allowing it more time
to be distributed to peripheral tissues.
Yokel and McNamara (82) found that the
systemic clearance was significantly lower
in renally impaired animals than renally
intact (39 compared to 53 ml/kg-hr),
whereas Meirav et al. (29) compared the
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systemic clearance of aluminum in a renal-
ly impaired rat to that in two normal rats
and found that the renal clearance was
similar. Ittel et al. (98) found that urinary
excretion of aluminum was greater in ure-
mic than in control rats, but ascribed their
results to greater absorption of aluminum
rather than greater clearance. A mechanism
postulated for an increase in absorption
was secondary hyperparathyroidism.
The aluminum toxicity experienced by
uremics may also be iatrogenic, through
exposure to aluminum in dialysis fluid.
This possibility has already been addressed
in the clinical setting: dialysis fluid is now
made from low-aluminum water, and
patients appear to suffer less aluminum
toxicity as a result (1).
An alternative explanation for Ittel's
observation of increased excretion of alu-
minum in uremia is that the free, or
ultrafiltrable, fraction is increased relative
to the protein-bound fraction. One study
found that a greater percentage of the alu-
minum added to serum from renally
impaired rabbits was free than in serum
from normal rabbits (82). However, Graf
et al. (99) found a negative relationship
between plasma aluminum concentration
and percent ultrafilterable aluminum in 24
dialysis patients. Another study (36) found
46% of the aluminum in serum ultra-
filtrate from 30 normal patients and 33%
of the aluminum in the ultrafiltrate from
30 uremic patients, with an increase in
non-ultrafiltrate aluminum as serum alu-
minum increased.
Alternatively, it is plausible that, in
uremia, potential aluminum-binding sites
on transferrin (and possibly albumin or
some other protein) are occupied by com-
peting ligand molecules that accumulate in
the blood. Excretion of aluminum would
thus be expected to increase with time after
onset of uremia, as competing ligands
accumulate, but this hypothesis has not
been investigated. Cochran et al. (79)
reported that the serum transferrin concen-
tration in dialysis patients is about 30 pM.
Given that serum aluminum concentra-
tions are higher than normal in these
patients, this reduction in aluminum-bind-
ing capacity may have implications for alu-
minum speciation.
As uremics also experience higher alu-
minum tissue burden and toxicity (95), it
may be that this fraction is more available
to tissues than the protein-bound fraction,
although tissue burden may reflect selective
retention rather than increased bioavail-
ability. Another explanation that has not
been examined is that tubular reabsorption
of aluminum occurs to a greater degree in
uremics.
Distribution ofAluminum to the
Central Nervous System
The brain appears to be one of the most
important target sites for aluminum toxici-
ty. The blood-brain barrier is normally
permeable only to small molecules, or larg-
er molecules, such as proteins, by active-
transport mechanisms. Because of this low
permeability, it is important to understand
the mechanisms by which aluminum per-
meates the barrier. Aluminum-protein
complexes are unlikely to permeate the
blood-brain barrier directly because of
their size, although transferrin-receptor-
mediated uptake is a possible mechanism
(100). Transferrin receptors are found in a
number of CNS cell types, including neu-
rons, oligodendrocytes, astrocytes, ependy-
mal cells (found in the spinal cord), and
choroid plexus cells (101). Transferrin is
believed to play a role in the development
of myelinated cells. In the presence of
other, smaller complexes, however, alu-
minum could cross the blood-brain barri-
er. A case study was reported of several
renal dialysis patients suffering from bone
aluminum toxicity who were treated with
desferrioxamine, an iron-chelating drug
that also efficiently chelates aluminum.
The subjects experienced neurological
symptoms resembling dialysis dementia;
several of them died. The investigators
conjectured that the resulting desferriox-
amine-aluminum complex, which is much
smaller and more soluble than alu-
minum-protein complexes, had distrib-
uted into the brain (102). Yokel et al.
(103) supported this hypothesis in a rat
study using microdialysis probes to moni-
tor aluminum-desferrioxamine distribu-
tion into various tissues, including the
brain.
Allen and Yokel (104 ) used in vivo
microdialysis to compare the permeabilities
of aluminum and gallium through the
blood-brain barrier with a view to using
gallium as a model for aluminum. They
found aluminum and gallium permeation
to be dissimilar. Gallium, although attrac-
tive because it possesses usable radioiso-
topes, therefore does not seem an appropri-
ate model for aluminum penetration into
the brain. Specifically, these investigators
found that aluminum permeates the brain
primarily at the cerebral capillaries, where-
as gallium permeates equally at the cerebral
capillaries and at the choroid plexuses. The
permeation of aluminum was nonsat-
urable, suggesting a nonspecific process
such as diffusion or pinocytosis of small-
molecule aluminum rather than binding of
aluminum-transferrin to cell-surface recep-
tors. The permeation of aluminum into
the brain could, however, be a combina-
tion of specific and nonspecific processes
and still appear nonsaturable overall, so
there still may be a role for transferrin.
Farrar et al. (105) used HPLC and gel
electrophoresis to study the binding of
radioactive gallium (which they presumed
to be analogous to aluminum) to transfer-
rin. Binding was lower in people with
either AD or Down's syndrome than in
normal subjects. The authors postulate
that reduced binding of gallium, and pre-
sumably aluminum, to transferrin could
lead to increased uptake of the metal across
the blood-brain barrier as a neutral citrate
complex. As discussed above, aluminum
appears to be taken up in a nonsaturable
fashion (i.e., nonspecifically), at least at the
cerebral capillaries (104).
Roskams and Connor (100) examined
the binding of aluminum-transferrin and
iron-transferrin to homogenized rat brain
and found evidence of a receptor that
binds both. Dissociation constants (Kd)
were 5.7 nM for iron-transferrin and 13.1
nM for aluminum-transferrin. The affinity
of this receptor for aluminum-transferrin,
although lower than that for iron-transfer-
rin, is still higher than the affinity of recep-
tors in other cells (such as hepatocytes and
lymphocytes) for iron-transferrin.
Unfortunately, homogenized rat brain is
probably not a good model for the
blood-brain barrier. These authors sug-
gested that aluminum's toxicity in the
brain might involve, at least in part, dis-
ruption of normal iron homeostasis and
iron-dependent cellular processes. Fleming
and Joshi (106) found that aluminum can
interfere with the rate of binding of iron to
ferritin, an iron-storage protein, in support
of Roskams and Connor's suggestion
(100).
Summary and Conclusions
A small fraction (0.1-1%) of aluminum
appears to be absorbed gastrointestinally
from the diet, possibly by iron-absorption
pathways. Upon reaching the serum,
80-90% of aluminum binds to the iron-
transport protein transferrin and, possibly,
to albumin; another aluminum-binding
protein that has not yet been well charac-
terized has also been tentatively identified.
The remaining 10-20% of aluminum
forms soluble (operationally defined as
ultrafiltrable), small-molecular complexes,
particularly with citrate and phosphate,
some of them hydrolyzed. Aluminum is
expected to be entirely soluble in serum
due to large excesses of complexing lig-
ands. Existing analytical techniques are,
however, inadequate to establish definitive-
ly the nature of the aluminum species pre-
sent in biological fluids. Equilibrium mod-
eling and nuclear magnetic resonance indi-
cate that most of the major species at phys-
iologic pH are charged. The only neutral
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species postulated is AI(OH)3' (aq), whose
existence has not been established and
which, in any case, appears, based on mod-
eling data, not to constitute a large fraction
of soluble aluminum species in serum.
The charged, soluble aluminum species
are unavailable for diffusion into tissues,
but are presumably readily excretable.
Receptors for transferrin, on the other
hand, exist in many cells, including at the
blood-brain barrier, and provide a means
for uptake of transferrin-bound aluminum
into tissues. Radionuclides of aluminum
are expensive, making tracer studies
difficult; atomic absorption spectroscopy is
the usual means of quantitating aluminum
in biological samples. Radioactive gallium
has been used as a model for aluminum
uptake, but its behavior does not appear to
be strictly comparable. Uptake of alu-
minum into brain and bone lead to toxici-
ty. Aluminum toxicity is of particular con-
cern to individuals with kidney impair-
ment, in whom aluminum concentrations
are higher.
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Turn a light off at home and you can save a few watts.
Turn it off in the woods and you can save an entire forest.
Only you can prevent forest fires.
A Public Service of the USDA Forest Service and your State Forester.
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